تعدد الأدوية لدى مرضى السكري من النوع الثاني المشاركين في برنامج برولانيس في إندونيسيا: تحديد التفاعلات الدوائية المحتملة
DOI:
https://doi.org/10.35516/jjps.v18i1.2783الكلمات المفتاحية:
التفاعلات الدوائية، تعدد الأدوية، برولانيس، مرض السكري من النوع الثانيالملخص
يصبح تحديد التفاعلات الدوائية المحتملة أمرًا بالغ الأهمية في تقييم سلامة الأدوية بين مرضى السكري. هدفت هذه الدراسة إلى تحديد التفاعلات الدوائية المحتملة للتعدد الدوائي لدى مرضى السكري من النوع 2 ((T2D في برنامج إدارة الأمراض المزمنة أو برنامج إدارة مرض السكري المزمن (PROLANIS). تم اختيار مرضى السكري من النوع 2 الذين تبلغ أعمارهم 18 عامًا أو أكثر على التوالي. تم تضمين عينة إجمالية من الوصفات الطبية التي تحتوي على 5 أدوية أو أكثر. كان متوسط عمر المرضى 62.70 ± 9.85 عامًا (المدى 24-92 عامًا)، وكان 62٪ منهم من كبار السن، و56.8٪ منهم من الإناث. كانت الوصفات الطبية للتعدد الدوائي أكثر انتشارًا في قسم الطب الباطني (92.8٪). من بين 250 وصفة طبية، احتوت حوالي 78.4٪ على تفاعل دوائي واحد على الأقل. تم تحديد ما مجموعه 515 تفاعل دوائي، بمتوسط تفاعلين دوائيين لكل مريض. ومن بين هذه الحالات، كانت 89.7% منها متوسطة الشدة. وكانت أزواج الأدوية المشاركة في pDDIs متوسطة الشدة هي جليمبيريد-ميتفورمين، جليمبيريد-بيسوبرولول، وميتفورمين-راميبريل. ويُعد عدد الأدوية لكل وصفة طبية مؤشرًا مهمًا لـ pDDIs (aOR = 7.48؛ 95% CI = 1.73-32.32). وكشف التحليل اللاحق أن الوصفات الطبية التي تحتوي على ثمانية أدوية أو أكثر كانت أكثر عرضة بنسبة 4.31 مرة لوجود أكثر من خمسة pDDIs (p = 0.010). يجب أن يلعب الصيادلة دورًا محوريًا في إدارة أدوية الأمراض المزمنة لتقليل مخاطر تفاعل الأدوية. تقترح هذه الدراسة تطوير نظام رقمي لمهنيي الرعاية الصحية لتحسين سلامة أدوية المرضى.
المراجع
Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019; 100(1): 32-38.
Guillot J, Maumus-Robert S, Bezin J. Polypharmacy: A general review of definitions, descriptions and determinants. Therapies. 2020; 75(5): 407-416. doi:10.1016/j.therap.2019.10.001 DOI: https://doi.org/10.1016/j.therap.2019.10.001
WHO. Medication Safety in Polypharmacy. Published online 2019. Accessed May 17, 2023. https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11
Hsein L, Srour S. Potential Drug-Drug Interactions and their Associated Factors at the University Children’s Hospital in Syria: A Cross-Sectional Study. Jordan Journal of Pharmaceutical Sciences. 2024; 17(1). DOI: https://doi.org/10.35516/jjps.v17i1.1606
Triplitt C. Drug Interactions of Medications Commonly Used in Diabetes. Diabetes Spectrum. 2006; 19(4): 202-211. doi:10.2337/diaspect.19.4.202 DOI: https://doi.org/10.2337/diaspect.19.4.202
Siddiqua A, Abdullah RK, Kareem NA. Impact of Clinical Pharmacist Intervention towards Polypharmacy in Elderly population-A Systematic Study. Rese Jour of Pharm and Technol. 2019; 12(6): 2621. doi:10.5958/0974-360X.2019.00439.6 DOI: https://doi.org/10.5958/0974-360X.2019.00439.6
Kwak MJ, Chang M, Chiadika S, et al. Healthcare Expenditure Associated With Polypharmacy in Older Adults With Cardiovascular Diseases. The American Journal of Cardiology. 2022; 169: 156-158. doi:10.1016/j.amjcard.2022.01.012 DOI: https://doi.org/10.1016/j.amjcard.2022.01.012
Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. The Lancet Healthy Longevity. 2021; 2(5): e290-e300. doi:10.1016/S2666-7568(21)00054-4 DOI: https://doi.org/10.1016/S2666-7568(21)00054-4
Hughes CM. One size fits all? How to optimize the prescribing of appropriate polypharmacy in chronic diseases, using a behavioral approach – a United Kingdom perspective. Expert Review of Clinical Pharmacology. 2022; 15(5): 497-499.
doi:10.1080/17512433.2022.2094767 DOI: https://doi.org/10.1080/17512433.2022.2094767
Humza AU, Siddiq A, Baig SG, Ali A, Ahmed I, Yousuf JB. Assessment of QTc-interval Prolonging Medication Utilization and Associated Potential Drug-Drug Interactions in Hospitalized Cardiac Patients: A Cross-Sectional Study in Cardiology. Jordan Journal of Pharmaceutical Sciences. 2024; 17(3). DOI: https://doi.org/10.35516/jjps.v17i3.2136
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice. 2019; 157:107843. doi:10.1016/j.diabres.2019.107843 DOI: https://doi.org/10.1016/j.diabres.2019.107843
Himanshu D, Ali W, Wamique M. Type 2 diabetes mellitus: pathogenesis and genetic diagnosis. J Diabetes Metab Disord. 2020; 19(2): 1959-1966. doi:10.1007/s40200-020-00641-x DOI: https://doi.org/10.1007/s40200-020-00641-x
Soeatmadji DW, Rosandi R, Saraswati MR, Sibarani RP, Tarigan WO. Clinicodemographic Profile and Outcomes of Type 2 Diabetes Mellitus in the Indonesian Cohort of DISCOVER: A 3-Year Prospective Cohort Study. JAFES. 2023; 38(1): 68-74. doi:10.15605/jafes.038.01.10 DOI: https://doi.org/10.15605/jafes.038.01.10
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. CDR. 2020; 16(5): 442-449.
doi:10.2174/1573399815666191024085838 DOI: https://doi.org/10.2174/1573399815666191024085838
Sonu S, Sharma G, Harikumar Sl, Navis S. A Review on Drug-Drug and Drug-Food Interactions in Patients During the Treatment of Diabetes Mellitus. IJPCS. 2016; 4(4): 98-105. doi:10.5530/ijpcs.4.4.6 DOI: https://doi.org/10.5530/ijpcs.4.4.6
Yosef B, Kaddar N, Boubou A. Evaluation of the Effect of Dapagliflozin on CRP Levels in Type 2 Diabetes Patients. Jordan Journal of Pharmaceutical Sciences. 2023; 16(2). DOI: https://doi.org/10.35516/jjps.v16i2.1331
Nowakowska M, Zghebi SS, Ashcroft DM, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019; 17(1): 145. doi:10.1186/s12916-019-1373-y DOI: https://doi.org/10.1186/s12916-019-1373-y
Rachmawati S, Prihhastuti-Puspitasari H, Zairina E. The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review. Journal of Basic and Clinical Physiology and Pharmacology. 2019; 30(6): 20190350.
doi:10.1515/jbcpp-2019-0350 DOI: https://doi.org/10.1515/jbcpp-2019-0350
Alkaff FF, Illavi F, Salamah S, et al. The Impact of the Indonesian Chronic Disease Management Program (PROLANIS) on Metabolic Control and Renal Function of Type 2 Diabetes Mellitus Patients in Primary Care Setting. J Prim Care Community Health. 2021; 12:215013272098440. doi:10.1177/2150132720984409 DOI: https://doi.org/10.1177/2150132720984409
Yusransyah Y, Halimah E, Suwantika AA. Measurement of the Quality of Life of Prolanis Hypertension Patients in Sixteen Primary Healthcare Centers in Pandeglang District, Banten Province, Indonesia, Using EQ-5D-5L Instrument. PPA. 2020; Volume 14:1103-1109. doi:10.2147/PPA.S249085 DOI: https://doi.org/10.2147/PPA.S249085
Yusransyah, Halimah E, Suwantika AA. Optimal scenario of antihypertension’s cost-effectiveness in Prolanis hypertension patients: A case study of Pandeglang District, Indonesia. Pharm Educ. 2022; 22(2): 85-91. doi:10.46542/pe.2022.222.8591 DOI: https://doi.org/10.46542/pe.2022.222.8591
Akbar Z, Rehman S, Khan A, Khan A, Atif M, Ahmad N. Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study. J of Pharm Policy and Pract. 2021; 14(1): 63. doi:10.1186/s40545-021-00348-1 DOI: https://doi.org/10.1186/s40545-021-00348-1
Rubina SS, Anuba P, Swetha B, Kalala KP, Aishwarya P, Sabarathinam S. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2022; 16(3): 102451.
doi:10.1016/j.dsx.2022.102451 DOI: https://doi.org/10.1016/j.dsx.2022.102451
Suriyapakorn B, Chairat P, Boonyoprakarn S, et al. Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases. Mogi M, ed. PLoS ONE. 2019; 14(11): e0225239. doi:10.1371/journal.pone.0225239 DOI: https://doi.org/10.1371/journal.pone.0225239
Hammar T, Hamqvist S, Zetterholm M, Jokela P, Ferati M. Current Knowledge about Providing Drug–Drug Interaction Services for Patients—A Scoping Review. Pharmacy. 2021; 9(2): 69.
doi:10.3390/pharmacy9020069 DOI: https://doi.org/10.3390/pharmacy9020069
Abdelkawy K, Kharouba M, Shendy K, et al. Prevalence of Drug–Drug Interactions in Primary Care Prescriptions in Egypt: A Cross-Sectional Retrospective Study. Pharmacy. 2023; 11(3): 106.
doi:10.3390/pharmacy11030106 DOI: https://doi.org/10.3390/pharmacy11030106
Mikhael EM, Hassali MA, Hussain SA, Mustafa MY. Assessment of Pharmacist’s Role in Counselling and Educating Diabetic Patients about Insulin Therapy. Int Res J Pharm. 2018; 9(7): 65-68. doi:10.7897/2230-8407.097127 DOI: https://doi.org/10.7897/2230-8407.097127
Hosen Z, Saha D, Khanam UH, et al. Evaluation of Drug-Drug Interaction in a Patient Drugs Profile with Multiple Complicacy and Patient Management. Research Journal of Pharmacy and Technology. 2012; 5(6).
Rendrayani F, Alfian SD, Wahyudin W, Puspitasari IM. Pharmacists’ Knowledge, Attitude, and Practice of Medication Therapy Management: A Systematic Review. Healthcare. 2022; 10(12): 2513.
doi:10.3390/healthcare10122513 DOI: https://doi.org/10.3390/healthcare10122513
Das S, Behera S, Xavier A, Dharanipragada S, Selvarajan S. Are drug-drug interactions a real clinical concern? Perspect Clin Res. 2019; 10(2): 62.
doi:10.4103/picr.PICR_55_18 DOI: https://doi.org/10.4103/picr.PICR_55_18
Saibi Y, Hasan D, Shaqila V. Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit X Tangerang Selatan. Jurnal Manajemen dan Pelayanan Farmasi. 2018; 8(3): 100-104. DOI: https://doi.org/10.22146/jmpf.34027
Trevisan DD, Silva JB, Póvoa VC, et al. Prevalence and clinical significance of potential drug-drug interactions in diabetic patients attended in a tertiary care outpatient center, Brazil. Int J Diabetes Dev Ctries. 2016; 36(3): 283-289. doi:10.1007/s13410-015-0428-7 DOI: https://doi.org/10.1007/s13410-015-0428-7
Cahyaningsih I, Wicaksono WA. Penilaian Risiko Interaksi Obat pada Pasien dengan Diabetes Melitus Tipe 2. ijcp. 2020; 9(1): 9. doi:10.15416/ijcp.2020.9.1.9 DOI: https://doi.org/10.15416/ijcp.2020.9.1.9
Sahay RK, Mittal V, Gopal GR, et al. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence. Cureus. Published online September 28, 2020. doi:10.7759/cureus.10700 DOI: https://doi.org/10.7759/cureus.10700
May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic Advances in Endocrinology. 2016; 7(2): 69-83.
doi:10.1177/2042018816638050 DOI: https://doi.org/10.1177/2042018816638050
Liang LR, Ma Q, Feng L, Qiu Q, Zheng W, Xie WX. Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. WJD. 2020; 11(4): 137-149. doi:10.4239/wjd.v11.i4.137 DOI: https://doi.org/10.4239/wjd.v11.i4.137
Nurlaelah I, Mukaddas A, Faustine I. Kajian Interaksi Obat pada Pengobatan Diabetes Melitus (DM) dengan Hipertensi di Instalasi Rawat Jalan RSUD Undata Periode Maret-Juni Tahun 2014. JFG. 2015; 1(1): 35-41. doi:10.22487/j24428744.2015.v1.i1.4833 DOI: https://doi.org/10.22487/j24428744.2015.v1.i1.4833
Itkonen M. Clinical Studies on Pharmacokinetic Drug-Drug Interactions Caused by Clopidogrel : Focus on CYP2C8-Mediated Drug Metabolism. Doctoral Thesis. University of Helsinki; 2019.
Wang H, Peng J, Wang B, et al. Inconsistency Between Univariate and Multiple Logistic Regressions. Shanghai Arch Psychiatry. 2017; 29(2): 124-128.
doi:10.11919/j.issn.1002-0829.217031
Lisni I, Lestari K, Rizka Andalusia L, Rahmawati D. Utilization of Expert Systems as a Source of Information in Detecting Drug Interactions in the Treatment of Diabetes Mellitus Patients: A Systematic Literature Review. RJPT. Published online January 27, 2023:328-332. doi:10.52711/0974-360X.2023.00058 DOI: https://doi.org/10.52711/0974-360X.2023.00058
Ibrahim M, Baker J, Cahn A, et al. Hypoglycaemia and its management in primary care setting. Diabetes Metabolism Res. 2020; 36(8): e3332. doi:10.1002/dmrr.3332 DOI: https://doi.org/10.1002/dmrr.3332
Upadhyay DK, Palaian S, Mishra P, Shankar PR, Anil SK, Bista D. Pattern of potential drug-drug interactions in diabetic out-patients in a Tertiary Care Teaching Hospital in Nepal. The Medical journal of Malaysia. 2007; 62(4): 294-298.
Murtaza G, Khan MYG, Azhar S, Khan SA, Khan TM. Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharmaceutical Journal. 2016; 24(2): 220-225. doi:10.1016/j.jsps.2015.03.009 DOI: https://doi.org/10.1016/j.jsps.2015.03.009
Sinuraya RK, Aini AN, Rahayu C, Wathoni N, Abdulah R. The Effectiveness of Postoperative Antibiotics following Appendectomy in Pediatric Patients: A Cost Minimization Analysis. TOPHJ. 2020; 13(1): 80-86. doi:10.2174/1874944502013010080 DOI: https://doi.org/10.2174/1874944502013010080
Siddiqui D e S. Role of healthcare professionals in drug-drug interactions and clinical interventions. European Journal of Clinical and Experimental Medicine. 2023; 21(1): 81-89. doi:10.15584/ejcem.2023.1.11 DOI: https://doi.org/10.15584/ejcem.2023.1.11
Barata J, Maia F, Mascarenhas A. Digital transformation of the mobile connected pharmacy: a first step toward community pharmacy 5.0. Informatics for Health and Social Care. 2022; 47(4): 347-360.
doi:10.1080/17538157.2021.2005603 DOI: https://doi.org/10.1080/17538157.2021.2005603
التنزيلات
منشور
كيفية الاقتباس
إصدار
القسم
